IMR Press / EJGO / Volume 24 / Issue 1 / pii/2003108

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Does adjuvant chemotherapy improve the prognosis of cervical carcinoma with lymph-node metastasis? A long-term follow-up

Show Less
1 Department of Gynecological Sciences, Perinatology and Child Health, I School of Medicine, Italy
2 Division of Obstetrics and Gynecology, Sant' Andrea Hospital, II School of Medicine, University of Rome “La Sapienza”, Italy
Eur. J. Gynaecol. Oncol. 2003, 24(1), 33–40;
Published: 10 February 2003

Objective: to verify the efficacy of adjuvant therapy in the prevention of neoplastic recurrence in patients at high risk for lymph­node involvement on surgical examination. Methods: 72 patients, suffering from squamous cell cervical carcinoma Stage IB-IIB (FIGO) who underwent radical hysterectomy with lymph-node involvement confirmed at the final histological examination, were enrolled. All the patients were treated with adjuvant chemotherapy (AC), which included cisplatin, bleomycin and vinblastine, and were followed for a minimum period of six years The results were compared with those obtained with a historical group of 78 patients, with comparable age, stage and lymph-node involvement, on whom only radical surgery (RS) was performed. Results: the average total survival rate of the two groups (RS + AC vs RS) at five years was 63.9% and 55.1 %, respectively (X2 = 1.191; p = NS). The disease-free interval was 55.6% vs 46.2% (X2=1.324; p = NS). The best results were obtained in cases where the common iliac lymph-nodes were affected, with the highest survival rate of I 6.9% in the RS+AC group, out of a total of 25 cases. Conclusions: adoption of adjuvant chemotherapy in patients at high risk for lymph-node positivity did not produce statistically significant results in terms of overall and disease-free survival; however, a small number of these patients, approximately 9%, could receive benefit from the treatment.

Cervical cancer
Adjuvant chemotherapy
Lymph-node metastasis
Back to top